Vanguard Group’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.4M | Sell |
7,765,138
-1,856,870
| -19% | -$6.31M | ﹤0.01% | 2429 |
|
|
2025
Q1 | $38.6M | Sell |
9,622,008
-2,094,835
| -18% | -$8.4M | ﹤0.01% | 2207 |
|
|
2024
Q4 | $76M | Sell |
11,716,843
-61,211
| -0.5% | -$397K | ﹤0.01% | 1979 |
|
|
2024
Q3 | $65.3M | Buy |
11,778,054
+31,876
| +0.3% | +$177K | ﹤0.01% | 2065 |
|
|
2024
Q2 | $65.5M | Sell |
11,746,178
-266,627
| -2% | -$1.49M | ﹤0.01% | 2043 |
|
|
2024
Q1 | $80.6M | Buy |
12,012,805
+122,105
| +1% | +$819K | ﹤0.01% | 1968 |
|
|
2023
Q4 | $108M | Buy |
11,890,700
+811,279
| +7% | +$7.4M | ﹤0.01% | 1825 |
|
|
2023
Q3 | $61.2M | Buy |
11,079,421
+461,142
| +4% | +$2.55M | ﹤0.01% | 2035 |
|
|
2023
Q2 | $90.7M | Buy |
10,618,279
+2,732,791
| +35% | +$23.3M | ﹤0.01% | 1908 |
|
|
2023
Q1 | $72.5M | Buy |
7,885,488
+114,421
| +1% | +$1.05M | ﹤0.01% | 1990 |
|
|
2022
Q4 | $79.3M | Buy |
7,771,067
+83,562
| +1% | +$853K | ﹤0.01% | 1932 |
|
|
2022
Q3 | $113M | Buy |
7,687,505
+1,413,703
| +23% | +$20.8M | ﹤0.01% | 1716 |
|
|
2022
Q2 | $67.3M | Sell |
6,273,802
-78,288
| -1% | -$840K | ﹤0.01% | 2045 |
|
|
2022
Q1 | $68.5M | Buy |
6,352,090
+5,140,344
| +424% | +$55.4M | ﹤0.01% | 2140 |
|
|
2021
Q4 | $19.8M | Buy |
1,211,746
+15,374
| +1% | +$251K | ﹤0.01% | 2847 |
|
|
2021
Q3 | $25.6M | Buy |
+1,196,372
| New | +$25.6M | ﹤0.01% | 2711 |
|